Home » Stocks » CYCN

Cyclerion Therapeutics, Inc. (CYCN)

Stock Price: $2.46 USD -0.13 (-4.84%)
Updated Apr 19, 2021 3:40 PM EDT - Market open
Market Cap 87.86M
Revenue (ttm) 2.30M
Net Income (ttm) -77.80M
Shares Out 33.96M
EPS (ttm) -2.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $2.46
Previous Close $2.58
Change ($) -0.13
Change (%) -4.84%
Day's Open 2.57
Day's Range 2.31 - 2.58
Day's Volume 348,235
52-Week Range 2.18 - 8.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive fun...

1 month ago - GlobeNewsWire

Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company's advancement of therapeutic pipeline candidates

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseas...

3 months ago - GlobeNewsWire

Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor

3 months ago - GlobeNewsWire

Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant i mprovements in multiple measures associated with age-related cognitive decline and neurodegenerative di...

5 months ago - GlobeNewsWire

A second midstage failure is hurting the biotech's stock price today.

6 months ago - The Motley Fool

Showed significant i mprovements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases

6 months ago - GlobeNewsWire

Study results do not support further internal development Study results do not support further internal development

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sG...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today...

7 months ago - GlobeNewsWire

-  IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively   -

8 months ago - GlobeNewsWire

 -  Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease  -

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today...

9 months ago - GlobeNewsWire

– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 –

1 year ago - GlobeNewsWire

– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative diseases –

1 year ago - GlobeNewsWire

The company evaluated praliciguat in 2 diseases, diabetic nephropathy and HFpEF, which are very complex and difficult-to-treat.

1 year ago - Forbes

A double clinical trial failure sends the biotech’s shares down.

1 year ago - The Motley Fool

Shares of Cyclerion Therapeutics Inc. plummeted 71% toward a record low Wednesday, to pace all premarket losers, after the biopharmaceutical company said a Phase 2 trial of its diabetes treatment missed...

1 year ago - Market Watch

About CYCN

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cy... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
CYCN
Full Company Profile

Financial Performance

In 2020, CYCN's revenue was $2.30 million, a decrease of -49.06% compared to the previous year's $4.51 million. Losses were -$77.80 million, -36.75% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CYCN stock is "Hold" and the 12-month stock price forecast is 4.00.

Price Target
$4.00
Analyst Consensus: Hold